Loading...
Loading...
Threshold
Pharmaceuticals, Inc.
THLD today announced that clinical
data on its investigational hypoxia-targeted drug, TH-302, will be
presented at the 55th Annual Meeting of the American Society of
Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The
presentations will report early data from two ongoing clinical
trials, one evaluating TH-302 as single-agent monotherapy in patients
with advanced leukemias (Abstract #3920), and another evaluating
TH-302 with low-dose dexamethasone in patients with
relapsed/refractory multiple myeloma (Abstract #1948).
Abstract Details
Abstract #1948: Phase 1 Study of TH-302, an Investigational
Hypoxia-Targeted Drug, and Dexamethasone in Patients with
Relapsed/Refractory Multiple Myeloma; 5:30 PM - 7:30 PM Central Time
on Saturday, December 7, 2013, in Hall G.
Abstract #3920: A Phase 1 Study of TH-302, an Investigational
Hypoxia-Targeted Drug, In Patients With Advanced Leukemias; 6:00 PM -
8:00 PM Central Time on Monday, December 9, 2013, in Hall E.
Abstracts are now available on the ASH website at www.hematology.org.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in